Fucoidan sulfate regulates Hmox1-mediated ferroptosis to ameliorate myocardial injury in diabetic cardiomyopathy.
10.19540/j.cnki.cjcmm.20241212.709
- Author:
Yu-Feng CAI
1
;
Wei HU
2
;
Yi-Gang WAN
3
;
Yue TU
4
;
Si-Yi LIU
5
;
Wen-Jie LIU
5
;
Liu-Yun-Xin PAN
5
;
Ke-Jia WU
6
Author Information
1. Department of Traditional Chinese Medicine,Drum Tower Clinical Medical College,Nanjing University of Chinese Medicine Nanjing 210008,China.
2. Department of Pharmacy,Nanjing Drum Tower Hospital,Affiliated Hospital of Medical School,Nanjing University Nanjing 210008,China.
3. Department of Traditional Chinese Medicine,Drum Tower Clinical Medical College,Nanjing University of Chinese Medicine Nanjing 210008,China Department of Traditional Chinese Medicine,Nanjing Drum Tower Hospital,Affiliated Hospital of Medical School,Nanjing University Nanjing 210008,China.
4. School of Acupuncture-Moxibustion and Tuina & School of Health Preservation and Rehabilitation,Nanjing University of Chinese Medicine Nanjing 210023,China Jiangsu Provincial Traditional Chinese Medicine Technology Engineering Research Center of Health and Health Preservation Nanjing 210023,China.
5. School of Acupuncture-Moxibustion and Tuina & School of Health Preservation and Rehabilitation,Nanjing University of Chinese Medicine Nanjing 210023,China.
6. Department of Traditional Chinese Medicine,Shangfang Community Health Service Center,Dongshan Street, Jiangning District Nanjing 211103,China.
- Publication Type:Journal Article
- Keywords:
Hmox1;
diabetic cardiomyopathy;
ferroptosis;
fucoidan sulfate;
network pharmacology
- MeSH:
Animals;
Ferroptosis/drug effects*;
Rats;
Diabetic Cardiomyopathies/physiopathology*;
Male;
Rats, Sprague-Dawley;
Polysaccharides/pharmacology*;
Heme Oxygenase-1/genetics*;
Myocytes, Cardiac/metabolism*;
Myocardium/pathology*;
Humans;
Cell Line;
Heme Oxygenase (Decyclizing)
- From:
China Journal of Chinese Materia Medica
2025;50(9):2461-2471
- CountryChina
- Language:Chinese
-
Abstract:
This study explores the role and underlying molecular mechanisms of fucoidan sulfate(FPS) in regulating heme oxygenase-1(Hmox1)-mediated ferroptosis to ameliorate myocardial injury in diabetic cardiomyopathy(DCM) through in vivo and in vitro experiments and network pharmacology analysis. In vivo, a DCM rat model was established using a combination of "high-fat diet feeding + two low-dose streptozotocin(STZ) intraperitoneal injections". The rats were randomly divided into four groups: normal, model, FPS, and dapagliflozin(Dapa) groups. In vitro, a cellular model was created by inducing rat cardiomyocytes(H9c2 cells) with high glucose(HG), using zinc protoporphyrin(ZnPP), an Hmox1 inhibitor, as the positive control. An automatic biochemical analyzer was used to measure blood glucose(BG), serum aspartate aminotransferase(AST), serum lactate dehydrogenase(LDH), and serum creatine kinase-MB(CK-MB) levels. Echocardiography was used to assess rat cardiac function, including ejection fraction(EF) and fractional shortening(FS). Pathological staining was performed to observe myocardial morphology and fibrotic characteristics. DCFH-DA fluorescence probe was used to detect reactive oxygen species(ROS) levels in myocardial tissue. Specific assay kits were used to measure serum brain natriuretic peptide(BNP), myocardial Fe~(2+), and malondialdehyde(MDA) levels. Western blot(WB) was used to detect the expression levels of myosin heavy chain 7B(MYH7B), natriuretic peptide A(NPPA), collagens type Ⅰ(Col-Ⅰ), α-smooth muscle actin(α-SMA), ferritin heavy chain 1(FTH1), solute carrier family 7 member 11(SLC7A11), glutathione peroxidase 4(GPX4), 4-hydroxy-2-nonenal(4-HNE), and Hmox1. Immunohistochemistry(IHC) was used to examine Hmox1 protein expression patterns. FerroOrange and Highly Sensitive DCFH-DA fluorescence probes were used to detect intracellular Fe~(2+) and ROS levels. Transmission electron microscopy was used to observe changes in mitochondrial morphology. In network pharmacology, FPS targets were identified through the PubChem database and PharmMapper platform. DCM-related targets were integrated from OMIM, GeneCards, and DisGeNET databases, while ferroptosis-related targets were obtained from the FerrDb database. A protein-protein interaction(PPI) network was constructed for the intersection of these targets using STRING 11.0, and core targets were screened with Cytoscape 3.9.0. Molecular docking analysis was conducted using AutoDock and PyMOL 2.5. In vivo results showed that FPS significantly reduced AST, LDH, CK-MB, and BNP levels in DCM model rats, improved cardiac function, decreased the expression of myocardial injury proteins(MYH7B, NPPA, Col-Ⅰ, and α-SMA), alleviated myocardial hypertrophy and fibrosis, and reduced Fe~(2+), ROS, and MDA levels in myocardial tissue. Furthermore, FPS regulated the expression of ferroptosis-related markers(Hmox1, FTH1, SLC7A11, GPX4, and 4-HNE) to varying degrees. Network pharmacology results revealed 313 potential targets for FPS, 1 125 targets for DCM, and 14 common targets among FPS, DCM, and FerrDb. Hmox1 was identified as a key target, with FPS showing high docking activity with Hmox1. In vitro results demonstrated that FPS restored the expression levels of ferroptosis-related proteins, reduced intracellular Fe~(2+) and ROS levels, and alleviated mitochondrial structural damage in cardiomyocytes. In conclusion, FPS improves myocardial injury in DCM, with its underlying mechanism potentially involving the regulation of Hmox1 to inhibit ferroptosis. This study provides pharmacological evidence supporting the therapeutic potential of FPS for DCM-induced myocardial injury.
